drugset / Trial / NCT03822637
The Effect of NAC on Lung Function and CT Mucus Score
RandomizedCrossoverTriple-blindTreatment
Summary
This study evaluates 20% n-acetylcysteine (NAC) in the treatment of moderate-to-severe asthma that is complicated by mucus in the airway, as determined by CT imaging. The study is a crossover design, which means that half the study participants will get 20% NAC in the first 14-day treatment period and placebo in the next 14-day treatment period; and the other half will get placebo in the first 14-day treatment period and 20% NAC in the next 14-day treatment period.
Timeline
- Start
- 2019-02-20
- Primary completion
- 2025-02-21
- Completion
- 2025-02-21
Publications
- Background Hays SR, Fahy JV. The role of mucus in fatal asthma. Am J Med. 2003 Jul;115(1):68-9. doi: 10.1016/s0002-9343(03)00260-2. No abstract available.
- Background DUNNILL MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol. 1960 Jan;13(1):27-33. doi: 10.1136/jcp.13.1.27.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-MONOACETYLCYSTINE | Small molecule | 3 ml | Other |
| Subject | N-MONOACETYLCYSTINE | Small molecule | 20 % | Other |
| Background | Salbutamol | Unknown | 0.5 ml | Other |
| Background | Salbutamol | Unknown | 2.5 mg | Other |